Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[212Pb] VMT alpha NET - Perspective Therapeutics

Next Previous
Drug Profile

[212Pb] VMT alpha NET - Perspective Therapeutics

Alternative Names: 212Pb alpha-particle radionuclide therapy; 212Pb-VMT-α-NET; [212Pb]PSC-PEG2-TOC

Latest Information Update: 09 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viewpoint Molecular Targeting
  • Developer Perspective Therapeutics
  • Class Antineoplastics; Lead radioisotopes; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours

Most Recent Events

  • 30 May 2025 Adverse events data from a phase I/II trial in Neuroendocrine tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 23 Jan 2025 Efficacy and adverse events data from a phase I/II trial in Neuroendocrine tumours presented at the 2025 Gastrointestinal Cancers Symposium (ASCO-GeCS-2025)
  • 04 Jul 2024 National Cancer Institute plans a phase I trial for Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Small Cell Lung cancer, Renal Cell cancer, and Head and Neck Cancers (Metastatic disease, Inoperable/Unresectable) in China (IV) in July 2024 (NCT06479811)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top